Literature DB >> 8438921

Colony-stimulating factor-1 in primary ascites of ovarian cancer is a significant predictor of survival.

F V Price1, S K Chambers, J T Chambers, M L Carcangiu, P E Schwartz, E I Kohorn, E R Stanley, B M Kacinski.   

Abstract

OBJECTIVE: Our purpose was to determine whether the concentration of colony-stimulating factor in ascites of ovarian carcinoma is a prognostic factor for survival. STUDY
DESIGN: Forty-four ascites samples from patients undergoing primary surgery for ovarian carcinoma were measured for colony-stimulating factor-1 by radioimmunoassay. Retrospective analysis of clinical data allowed comparison of accepted prognostic factors to ascites colony-stimulating factor-1 concentration for impact on survival by means of life-table analysis (Kaplan-Meier) by the Wilcoxon test and the Cox regression methods.
RESULTS: In patients with advanced disease (International Federation of Gynecology and Obstetrics stages III and IV, n = 37) ascites colony-stimulating factor-1 concentration levels below a critical cutoff of 8.59 ng/ml were associated with longer overall survival (p < 0.05) and were a better predictor of survival than any other prognostic factor except zero residual disease after cytoreduction. International Federation of Gynecology and Obstetrics stage, tumor histologic type, malignant cells in fluid, grade of tumor, age, and performance status at presentation were not predictive of outcome.
CONCLUSION: Colony-stimulating factor-1 in ascites may be an independent indicator of prognosis in patients with epithelial ovarian cancer.

Entities:  

Mesh:

Substances:

Year:  1993        PMID: 8438921     DOI: 10.1016/0002-9378(93)90485-2

Source DB:  PubMed          Journal:  Am J Obstet Gynecol        ISSN: 0002-9378            Impact factor:   8.661


  12 in total

Review 1.  The macrophage growth factor CSF-1 in mammary gland development and tumor progression.

Authors:  Elaine Y Lin; Valerie Gouon-Evans; Andrew V Nguyen; Jeffrey W Pollard
Journal:  J Mammary Gland Biol Neoplasia       Date:  2002-04       Impact factor: 2.673

Review 2.  Adenocarcinoma cells in effusion cytology as a diagnostic pitfall with potential impact on clinical management: a case report with brief review of immunomarkers.

Authors:  Sinchita Roy Chowdhuri; Patricia Fetsch; Jennifer Squires; Elise Kohn; Armando C Filie
Journal:  Diagn Cytopathol       Date:  2012-11-16       Impact factor: 1.582

3.  Macrophage Blockade Using CSF1R Inhibitors Reverses the Vascular Leakage Underlying Malignant Ascites in Late-Stage Epithelial Ovarian Cancer.

Authors:  Diana L Moughon; Huanhuan He; Shiruyeh Schokrpur; Ziyue Karen Jiang; Madeeha Yaqoob; John David; Crystal Lin; M Luisa Iruela-Arispe; Oliver Dorigo; Lily Wu
Journal:  Cancer Res       Date:  2015-10-15       Impact factor: 12.701

Review 4.  Macrophages in ovarian cancer and their interactions with monoclonal antibody therapies.

Authors:  Gabriel Osborn; Chara Stavraka; Rebecca Adams; Ahmad Sayasneh; Sharmistha Ghosh; Ana Montes; Katie E Lacy; Rebecca Kristeleit; James Spicer; Debra H Josephs; James N Arnold; Sophia N Karagiannis
Journal:  Clin Exp Immunol       Date:  2022-07-22       Impact factor: 5.732

5.  Enhanced ovarian cancer tumorigenesis and metastasis by the macrophage colony-stimulating factor.

Authors:  Eugene P Toy; Masoud Azodi; Nancy L Folk; Christina M Zito; Caroline J Zeiss; Setsuko K Chambers
Journal:  Neoplasia       Date:  2009-02       Impact factor: 5.715

Review 6.  Role of CSF-1 in progression of epithelial ovarian cancer.

Authors:  Setsuko K Chambers
Journal:  Future Oncol       Date:  2009-11       Impact factor: 3.404

7.  The multifunctional protein glyceraldehyde-3-phosphate dehydrogenase is both regulated and controls colony-stimulating factor-1 messenger RNA stability in ovarian cancer.

Authors:  Yi Zhou; Xiaofang Yi; Jha'nae B Stoffer; Nathalie Bonafe; Maureen Gilmore-Hebert; Jessica McAlpine; Setsuko K Chambers
Journal:  Mol Cancer Res       Date:  2008-08       Impact factor: 5.852

Review 8.  Targeting macrophages: therapeutic approaches in cancer.

Authors:  Luca Cassetta; Jeffrey W Pollard
Journal:  Nat Rev Drug Discov       Date:  2018-10-26       Impact factor: 84.694

9.  Synthesis and breakdown of fibrillar collagens: concomitant phenomena in ovarian cancer.

Authors:  M Santala; J Risteli; L Risteli; U Puistola; B M Kacinski; E R Stanley; A Kauppila
Journal:  Br J Cancer       Date:  1998-06       Impact factor: 7.640

10.  Autocrine CSF-1R activation promotes Src-dependent disruption of mammary epithelial architecture.

Authors:  Carolyn N Wrobel; Jayanta Debnath; Eva Lin; Sean Beausoleil; Martine F Roussel; Joan S Brugge
Journal:  J Cell Biol       Date:  2004-04-26       Impact factor: 10.539

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.